Park Avenue Securities LLC Makes New Investment in Natera, Inc. $NTRA

Key Points

• Park Avenue Securities LLC has acquired a new stake in Natera, Inc., purchasing 9,029 shares valued at approximately $1,525,000 during Q2.
• Natera reported a loss of ($0.74) EPS, missing analysts' expectations while revenue increased by 32.2% year-over-year, totaling $546.60 million.
• Analyst ratings for Natera are optimistic, with target prices set as high as $268.00, reflecting a consensus price target of $192.88.

Park Avenue Securities LLC purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 9,029 shares of the medical research company's stock, valued at approximately $1,525,000.

Several other institutional investors have also recently made changes to their positions in the company. Bank of Jackson Hole Trust bought a new stake in shares of Natera in the 1st quarter valued at about $29,000. Rakuten Securities Inc. increased its holdings in Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after buying an additional 119 shares during the period. ORG Partners LLC purchased a new position in Natera during the first quarter valued at approximately $32,000. TCTC Holdings LLC increased its holdings in Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after buying an additional 124 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in Natera by 83.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock valued at $33,000 after buying an additional 106 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Price Performance

Shares of NTRA stock opened at $163.66 on Friday. Natera, Inc. has a 1-year low of $117.27 and a 1-year high of $183.00. The stock's fifty day moving average price is $158.39 and its 200 day moving average price is $155.85. The company has a market cap of $22.46 billion, a price-to-earnings ratio of -85.69 and a beta of 1.68.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. During the same quarter in the previous year, the firm posted ($0.30) EPS. Natera's revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Cowen reiterated a "buy" rating on shares of Natera in a report on Friday, August 8th. Barclays reiterated an "overweight" rating and issued a $210.00 target price (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. Piper Sandler reiterated an "overweight" rating and issued a $220.00 target price (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. Royal Bank Of Canada set a $268.00 target price on Natera and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. Finally, Stephens reaffirmed an "overweight" rating and issued a $183.00 price objective on shares of Natera in a research report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Natera presently has an average rating of "Buy" and a consensus price target of $192.88.

Insider Activity at Natera

In other Natera news, insider John Fesko sold 678 shares of the business's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $155.46, for a total transaction of $105,401.88. Following the sale, the insider owned 152,747 shares of the company's stock, valued at approximately $23,746,048.62. The trade was a 0.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $166.62, for a total transaction of $499,860.00. Following the sale, the insider directly owned 120,859 shares in the company, valued at $20,137,526.58. This trade represents a 2.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 56,423 shares of company stock worth $8,459,656 in the last 90 days. 5.63% of the stock is owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.